|Bid||3.05 x 2000|
|Ask||3.47 x 2000|
|Day's Range||3.28 - 3.37|
|52 Week Range||1.93 - 3.77|
|PE Ratio (TTM)||7.56|
|Dividend & Yield||0.00 (0.00%)|
|1y Target Est||N/A|
Pluristem Therapeutics' (PSTI) phase III study of PLX-PAD cells in patients with critical limb ischemia granted Fast Track designation by the FDA.
The biotech sector has turned around after its dismal performance in 2016 as uncertainty surrounding drug pricing control subsides. A few stocks are however still undervalued, which may gain going ahead.
PDL BioPharma, Inc. (PDLI) is seeing solid earnings estimate revisions, and the stock is showing decent short-term momentum as well.